Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) will likely be announcing its Q1 2025 earnings results before the market opens on Tuesday, May 6th. Analysts expect Voyager Therapeutics to post earnings of ($0.35) per share and revenue of $13.55 million for the quarter.
Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.18). The company had revenue of $6.47 million during the quarter, compared to the consensus estimate of $13.55 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. On average, analysts expect Voyager Therapeutics to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Voyager Therapeutics Stock Down 5.5 %
VYGR traded down $0.19 during trading on Friday, reaching $3.24. The stock had a trading volume of 756,113 shares, compared to its average volume of 445,631. Voyager Therapeutics has a 1-year low of $2.75 and a 1-year high of $9.55. The firm has a market capitalization of $179.21 million, a price-to-earnings ratio of 4.56 and a beta of 0.95. The stock has a 50 day moving average of $3.52 and a two-hundred day moving average of $4.93.
Wall Street Analysts Forecast Growth
A number of research analysts recently issued reports on the company. Canaccord Genuity Group lowered their target price on Voyager Therapeutics from $14.00 to $12.00 and set a "buy" rating on the stock in a report on Thursday, March 13th. Wedbush reissued an "outperform" rating on shares of Voyager Therapeutics in a research note on Wednesday, March 12th. Wells Fargo & Company set a $10.00 price target on Voyager Therapeutics and gave the company an "overweight" rating in a report on Wednesday, March 12th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $13.97.
Get Our Latest Analysis on Voyager Therapeutics
Insider Activity at Voyager Therapeutics
In other Voyager Therapeutics news, CEO Alfred Sandrock sold 10,885 shares of Voyager Therapeutics stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total transaction of $37,335.55. Following the transaction, the chief executive officer now owns 430,931 shares of the company's stock, valued at $1,478,093.33. The trade was a 2.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 6.39% of the stock is owned by insiders.
Voyager Therapeutics Company Profile
(
Get Free Report)
Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.
Recommended Stories

Before you consider Voyager Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Voyager Therapeutics wasn't on the list.
While Voyager Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.